<DOC>
	<DOCNO>NCT01214239</DOCNO>
	<brief_summary>In randomise , double-blind , parallel group trial , safety efficacy 5 mg Linagliptin administer orally daily compare placebo 24 week treatment monotherapy patient type 2 diabetes insufficient glycaemic control .</brief_summary>
	<brief_title>Efficacy Safety Study Linagliptin ( 5 mg Administered Orally Once Daily ) Over 24 Weeks , Drug na√Øve Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient diagnosis type 2 diabetes mellitus , either treatment naive treat one antidiabetic medication . Antidiabetic therapy unchanged 6 week prior inform consent 2 . Diagnosis type 2 diabetes prior inform consent 3 . Glycosylated haemoglobin A1 ( HbA1c ) Visit 1a ( Screening ) : For patient undergo wash previous medication : HbA1c =7.0to =9.5 % For patient undergo washout previous medication : HbA1c =7.0 =10.0 % 4 . Glycosylated haemoglobin A1 ( HbA1c ) =7.0 =10.0 % Visit 2 ( Start Runin ) 5 . Age = 18 &lt; 80 year Visit 1a ( Screening ) 6 . BMI ( Body Mass Index ) = 45 kg/m2 Visit 1a ( Screening ) 7 . Signed date write informed consent date Visit 1a accordance GCP local legislation Exclusion criterion : 1 . Myocardial infarction , stroke TIA within 6 month prior inform consent 2 . Impaired hepatic function , define serum level either Alanine transaminase ( SGPT ) , Aspartate transaminase ( SGOT ) , alkaline phosphatase 3 x upper limit normal ( ULN ) determine Visit 1a 3 . Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast washout / placebo runin confirm second measurement ( day ) 4 . Known hypersensitivity allergy investigational product excipients 5 . Treatment one antidiabetic drug within 6 week prior inform consent 6 . Treatment rosiglitazone pioglitazone within 3 month prior inform consent 7 . Treatment Glucagonlike peptide 1 ( GLP1 ) analogue ( e.g . exenatide ) , DipeptidylPeptidase 4 ( DPPIV ) inhibitor within 3 month prior inform consent 8 . Treatment insulin within 3 month prior inform consent 9 . Treatment antiobesity drug ( e.g . sibutramine , orlistat , rimonabant ) within 3 month prior inform consent 10 . Alcohol abuse within 3 month prior inform consent would interfere trial participation drug abuse 11 . Participation another trial investigational drug within 2 month prior inform consent 12 . Premenopausal woman ( last menstruation = 1 year prior informed consent ) : nursing pregnant , childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include transdermal patch , intrauterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , sexual abstinence vasectomise partner . No exception make . 13 . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent . 14 . Renal failure renal impairment ( serum creatinine =1.5 mg/dl determine Visit 1a ) 15 . Dehydration clinical judgement investigator 16 . Unstable acute congestive heart failure 17 . Acute chronic metabolic acidosis ( present patient history ) 18 . Hereditary galactose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>